The Full Answer
Intraosseous injection is best understood as a joint-preservation strategy, not a replacement-avoidance guarantee. By targeting the bone marrow lesion that often drives pain and progression, the goal is to reduce symptoms and potentially slow further deterioration for as long as the joint's underlying structure allows — buying time, not curing the arthritis.
What the Current Evidence Shows
Philippe Hernigou's randomized study following patients for fifteen years found that subchondral (intraosseous) bone marrow concentrate injection helped postpone knee arthroplasty in a meaningful subset of patients compared to a control group — one of the longer-term data points supporting this framing, though not a universal outcome.
Who May Benefit
Patients with early to moderate knee osteoarthritis, remaining joint space on X-ray, and an active bone marrow lesion, who are motivated to delay replacement surgery and understand the treatment may need to be repeated.
When Surgery May Be More Appropriate
Once a knee is bone-on-bone, mechanically unstable, or disrupting sleep and basic function despite conservative and orthobiologic care, intraosseous injection is unlikely to meaningfully change that trajectory, and joint replacement should be discussed honestly rather than delayed further.
Dr. Tortland's Perspective
Dr. Tortland is direct with patients about this trade-off: intraosseous injection can be a legitimate way to buy time in the right candidate, but it isn't a substitute for surgery once a joint is truly worn out — and he'd rather have that conversation early than let a patient chase injections past the point they still help.